Abstract
The cannabinoid CB2 receptor was cloned from the promyeloid cell line HL-60 and is notably expressed in most, if not all leukocyte types. This relatively restricted localization, combined to the absence of psychotropic effects following its activation, make it an attractive drug target for inflammatory and autoimmune diseases. Therefore, there has been an increasing interest in the past decades to identify precisely which immune cells express the CB2 receptor and what are the consequences of such activation. Herein, we provide new data on the expression of both CB1 and CB2 receptors by human blood leukocytes and discuss the impact of CB2 receptor activation in human leukocytes. While the expression of the CB2 mRNA can be detected in eosinophils, neutrophils, monocytes, B and T lymphocytes, this receptor is most abundant in human eosinophils and B lymphocytes. We also review the evidence obtained from primary human leukocytes and immortalized cell lines regarding the regulation of their functions by the CB2 receptor, which underscore the urgent need to deepen our understanding of the CB2 receptor as an immunoregulator in humans.
Introduction
The cannabinoid receptors 1 and 2 (CB1 and CB2) are two G protein-coupled receptors that function through binding a vast array of ligands including phytocannabinoids and endocannabinoids (Di Marzo et al., 1998; Turcotte et al., 2015). The CB1 receptor, highly expressed in the brain, was the first cannabinoid receptor identified through its responsiveness to Δ9-tetrahydrocannabinol (Δ9-THC) and cloned (Devane et al., 1988; Matsuda et al., 1990). Its activation induces psychotropic effects and its involvement shown in, among others, motor function, cognition and memory (Howlett and Abood 2017). It is also widely recognized as worsening obesity and related diseases (Di Marzo 2018). The CB2 receptor was later cloned from HL-60 cells and identified on its 44% aminoacid homology with the CB1, as well as its similar binding profile to the endocannabinoid N-arachidonoyl-ethanolamine (AEA) and Δ9-THC (Munro et al., 1993). Soon after, Galiègue et al. documented that it was expressed by human leukocytes (Galiegue et al., 1995). This consolidated the concept that the CB2 is the peripheral cannabinoid receptor and, for many, the inflammatory cannabinoid receptor. In fact, the CB2 receptor has been found in all leukocyte populations tested so far [see (Turcotte et al., 2016) for a review]. However, CB2 receptor expression is not restricted to leukocytes. It has notably been found in resident immune brain cells (microglia), the kidney, spleen, tonsil, thymus, lung epithelial cells and testes (Sanchez et al., 2001; Brown et al., 2002; Van Sickle et al., 2005; Ellert-Miklaszewska et al., 2007; Zhou et al., 2018; Cakir et al., 2019; Fantauzzi et al., 2020).
Expression of the CB1 and CB2 Receptors by Human Blood Leukocytes
Galiègue et al. paved the way to our understanding of CB2 expression by human leukocytes by showing its mRNA was expressed in human leukocytes, with the following order of relative abundance: tonsillar B cells > natural killer cells > monocytes ∼ granulocytes > T4 lymphocytes > T8 lymphocytes (Galiegue et al., 1995). While very informative and useful, the data from Galiègue et al. did not include eosinophils while including tissue instead of blood B lymphocytes. This was somewhat pointed out in following studies (Turcotte et al., 2016), as it might have led to some inconsistencies. For example, while some documented the expression of the CB2 receptor in human granulocytes (neutrophils and contaminating eosinophils) (Galiegue et al., 1995; Kurihara et al., 2006), others did not (Oka et al., 2004; Graham et al., 2010). This raised the possibility that contaminating cells might have been responsible for the previously documented CB2 signal in neutrophils, and possibly other cell types. Noteworthy, it was later reported that eosinophil-depleted neutrophils weakly expressed the CB2 receptor mRNA, while eosinophils (the main neutrophil suspension contaminant) expressed it at high levels, raising the strong possibility that discrepancies regarding CB2 expression in neutrophils could be the result of contaminating eosinophils in granulocyte preparations (Chouinard et al., 2013). CB2 expression was also reported in human eosinophils in other studies (Frei et al., 2016; Larose et al., 2017; Freundt-Revilla et al., 2018; Dothel et al., 2019).
In an attempt to better define CB2 expression in human blood leukocytes, we revisited its expression by qPCR using mRNA from leukocytes that were isolated from the blood of healthy volunteers. CB1 receptor expression was assessed in parallel. Hypothalamus samples were utilized as positive controls for the CB1 receptor. In our hands, all tested leukocytes expressed the CB1 receptor mRNA although to a lesser extent than hypothalamus samples (Figure 1A). In contrast, while we detected the expression of the CB2 receptor mRNA in all leukocyte and hypothalamus samples, human eosinophils and B lymphocytes displayed the strongest signals (Figure 1B). Thus, these cell types are likely the origin of CB2 expression found in mixed populations such as granulocytes (neutrophils and eosinophils, often abbreviated as PMN) and PBMCs (monocytes, B and T lymphocytes). This underlines the importance of separating granulocytes and PBMCs when studying the CB2 receptor. The small, but detectable levels of CB2 receptor mRNA in hypothalamus samples are consistent with other studies reporting its expression in this tissue (Sanchez et al., 2001; Van Sickle et al., 2005; Ellert-Miklaszewska et al., 2007).
FIGURE 1
Factors Influencing CB2 Receptor Expression in Human Leukocytes
Some factors were documented as influencing CB2 receptor expression in human leukocytes. CB2 expression can increase during inflammation as it is the case in eosinophils from symptomatic allergic donors compared to healthy controls (Frei et al., 2016; Larose et al., 2017), in monocytes of patients after ischemic stroke (Greco et al., 2021), in myeloid and plasmacytoid dendritic cells of patients with multiple sclerosis (Chiurchiu et al., 2013; Sanchez Lopez et al., 2015) and in T lymphocytes of Non-Hodgkin’s lymphomas (Rayman et al., 2007; Robinson et al., 2013). On the other hand, LPS decreased CB2 receptor expression in isolated dendritic cells and B lymphocytes (Lee et al., 2001; Do et al., 2004). Finally, the CB2 receptor was not detected in resting macrophages, was present at high levels in responsive and primed cells and was greatly diminished in fully activated cells (Cabral 2010). The latter observation suggests that the CB2 receptor might have a time-specific function in macrophages during inflammation.
Numerous CB2 receptor antibodies have been developed but most (if not all) are failing to provide reliable signals in different applications (immunohistochemistry, cytofluorometry and immunoblot), while not always having been characterized with the appropriate controls (control peptide blockade, CB2 receptor-devoid cells, cross reactivity). Thus, until a clear consensus is achieved on which antibodies are sufficiently reliable, data on CB2 protein should be interpreted with caution. With that in mind, the CB2 receptor protein localization can vary. Indeed, Castaneda et al. reported that the CB2 receptor protein was found intracellularly in most leukocytes with only B lymphocytes expressing it at the extracellular membrane (Castaneda et al., 2013). CB2-positive B lymphocytes were mainly located in the mantle of secondary lymphoid follicles, which contain immature B lymphocytes while some positive cells also appeared in the germinal centers of secondary follicles, which contain mature B lymphocytes, suggesting an heterogeneous distribution of the receptor during B lymphocytes maturation stages (Galiegue et al., 1995). Immunohistochemical analysis using an N-terminal specific anti-CB2 antibody revealed high protein expression in the germinal centers of secondary follicles while a C-terminal specific anti-CB2 antibody (only recognizing a non-phosphorylated inactive receptor) showed positivity primary follicle, the mantle and marginal zones of the secondary follicles where resting cells reside (Rayman et al., 2004). Therefore, active CB2 seems mainly present on B lymphocytes in the germinal centers.
Impact of CB2 Receptor Activation in Human Leukocytes
The early studies investigating the roles of the CB2 receptor, notably those involving cnr2-deficient mice, led to the idea that it is mainly anti-inflammatory (Turcotte et al., 2016). However, recent studies are emerging and indicate that the outcome of CB2 receptor signaling may differ depending on the experimental model/disease. A good example is experimental asthma. Indeed, early work indicated that the CB2 receptor agonist WIN 55,212-2 inhibited ovalbumin-induced plasma extravasation in guinea pig airways (Fukuda et al., 2010). In contrast, the CB2 receptor agonist JWH-133 aggravated ovalbumin-induced asthma in mice while having no effect in dinitrofluorobenzene-induced asthma (Bozkurt et al., 2016; Frei et al., 2016). When house dust mites were utilized as allergen, cnr2-deficient mice were resistant to allergic responses (Ferrini et al., 2017) while an innate lymphoid cell-2 dependent model involving IL-25, IL-33 and/or Alternaria alternate had lower symptoms, decreased eosinophil number, and airway resistance (Hurrell et al., 2021). In humans, CB2 receptor expression was increased in nasal polyps of aspirin-exacerbated disease patients (Corrado et al., 2018) while being decreased in epithelial cells of asthmatic patients (Fantauzzi et al., 2020).
While we address some leukocytes individually below, the overall impact of CB2 receptor activation on human leukocytes is summarized in Table 1. However, we underscore that the selectivity of the pharmacological tools targeting CB2 receptors (agonists, antagonists, inverse agonists) has been often questioned, as exemplified by the work of Soethoudt et al. (2017).
TABLE 1
| Leukocytes or cell lines | Agonist | Antagonist or inverse agonist | Effects | Impact on signaling | References | |
|---|---|---|---|---|---|---|
| Eosinophils | ||||||
| Blood | 2-AG | 1 μM (4 h) | SR144528 (1 μM) | Induce migration in presence of 1 μM NDGA (lipoxygenase inhibitor) | Oka et al. (2004) | |
| 1 μM (1 h) | SR144528 (1 μM) | 2-AG-induced migration in presence of 1 μM NDGA is attributed to chemotaxis rather than chemokinesis | Kishimoto et al. (2006) | |||
| 3 μM (2 h) | SR144528 (10 μM) | Induce migration in presence of IL-5 | Inhibited by the Lyn inhibitor PP2 | Larose et al. (2014) | ||
| AM630 (10 μM) | ||||||
| 250 nM (5 h) | SR144528 (1 μM) | ↑ CCL24-induced shape change and migration | Frei et al. (2016) | |||
| CP 55,940 | 1 μM (2 h) | - | No effect on migration | Larose et al. (2014) | ||
| JWH-133 | 100–250 nM (5 h) | SR144528 (1 μM) | Induce migration | Migration inhibited by MEK1 inhibitors (U-0126, PD98,059) and the ROCK inhibitor Y-27632 | Frei et al. (2016) | |
| ↑ CCL24-induced shape change and migration | Not inhibited by pertussis toxin (PTX; Gαi-independant), p38 or PI3K inhibitors | |||||
| ↑ CCL24-induced CD11b upregulation | - ↑ Ca2+ influx | |||||
| ↑ Adhesion to ICAM-1 | - Ca2+ influx inhibited by the PLC inhibitor U-73122 and the IP3 receptor antagonist 2-APB | |||||
| Leukemia EoL-1 cells | 2-AG | 1 μM (4 h) | SR144528 (1 μM) | Induce migration in presence of 1 μM NDGA | Inhibited by PTX (Gi/0-dependant) | Oka et al. (2004) |
| S-777469 | 100–500 nM (4 h) | - | ↓ 2-AG-induced migration | Haruna et al. (2017) | ||
| B lymphocytes | ||||||
| Blood | CP 55,940 | 1–100 nM (72 h) | SR144528 (100–300 nM) | ↑ Proliferation | Carayon et al. (1998) | |
| Tonsillar | CP 55,940 | 1–100 nM (72 h) | SR144528 (100–300 nM) | ↑ Proliferation of both naïve and germinal centrosome B lymphocytes | Carayon et al. (1998) | |
| WIN 55,212–2 | 10 μM (4 h) | SR144528 (10 nM) | No effect | Gustafsson et al. (2006) | ||
| Raji cell line | 2-AG | 300 nM (4 h) | SR144528 (100 nM) | Induce moderate migration | Rayman et al. (2004) | |
| ↑ Migration following stimulation with an anti-sCD40 antibody | ||||||
| Rec-1 cell line | WIN 55,212–2 | 10 μM (4 h) | SR144528 (10 nM) | ↑ Apoptosis (caspase-3 activity) | - Inhibited by the CB1 inverse agonist SR141716A and by p38 inhibitors | Gustafsson et al. (2006) |
| ↑ Ceramide levels (downstream of p38 activation) | - Not inhibited by c-Jun or MEK-1 inhibitors | |||||
| SKW 6.4 cell line | - | SR144528 (5–10 μM) | ↓ IL-6 induced secretion of soluble IgM | - Inhibited by the CB2 agonist HU308 | Feng et al. (2014) | |
| AM630 (5 μM) | - ↓ IL-6-induced p-STAT3 | - Do not degrade IκBα as the NF-κB inhibitor Bay11-7085 | ||||
| - ↑ Pax5 (first) and Bcl-6 mRNA levels | ||||||
| Neutrophils | ||||||
| Blood | 2-AG | 1 μM (4 h) | SR144528 (1 μM) | No effect on migration in presence of NDGA | Oka et al. (2004) | |
| 300 nM (20 min) | SR144528 (1 μM) | No motility or morphologic alterations | Kurihara et al. (2006) | |||
| JWH-015 | 100 nM-10 μM (20 min) | SR144528 (1 μM) | No motility or morphologic alterations | Kurihara et al. (2006) | ||
| JWH-133 | 1 μM (2 h) | - | No effect on neutrophil function | Zhou et al. (2020) | ||
| 100 nM (5 h) | SR144528 (1 μM) | No effect on IL-8-induced migration | Frei et al. (2016) | |||
| 100 nM-1 μM (30 min) | AM630 (500 nM) | ↓ LPS-induced VEGF-A | Braile et al. (2021) | |||
| ↓ LPS-induced endothelial permeability | ||||||
| T lymphocytes | ||||||
| Blood | AEA | 0.5–5 μM (6 h) | SR144528 (1 μM) | ↓ Proliferation | Cencioni et al. (2010) | |
| ↓ IL-2, TNF-α and IFN-γ | ||||||
| ↓ IL-17 | ||||||
| JWH-015 | 20 μM (1 h) | AM630 (500 nM) | ↓ CXCL12-induced chemotaxis | Ghosh et al. (2006) | ||
| 250 nM (2 h) | AM630 (500 nM) | ↓ Proliferation | ↓ p-ERK1/2 | Borner et al. (2009) | ||
| ↓ IL-2 | ||||||
| 1 μM (6 h) | SR144528 (1 μM) | ↓ Proliferation | Cencioni et al. (2010) | |||
| ↓ IL-2, TNF-α and IFN-γ | ||||||
| ↓ IL-17 | ||||||
| 1 μM (1–30 min) | AM630 (1 μM) | ↓ HIV-1 infection in primary CD4 T cells | Costantino et al. (2012) | |||
| JWH-133 | 0.001–10 μM (30 min) | - | ↓ CXCL12-induced chemotaxis | ↑ p-ERK1/2 | Coopman et al. (2007) | |
| 100 nM-1 μM (1–30 min) | AM630 (1 μM) | ↓ HIV-1 infection in primary CD4 T cells | ↓ p-ERK1/2 and p-Akt | Costantino et al. (2012) | ||
| ↓ Activation of CXCR4 by SDF-1α | ||||||
| ↓ Levels of F-actin | ||||||
| Δ9-THC | 5 μg/ml (18 h) | SR144528 (1 μM) | ↓ Percentage of T lymphocytes expressing IFN-γ | Yuan et al. (2002) | ||
| ↓ IFN-γ intracellular level detected per cell | ||||||
| ↑ IL-4 and IL-5 | ||||||
| Jurkat cells | GW 405833 | 10–40 μM (3–24 h) | AM630 (1 μg/ml) | ↓ Cell viability | Huang et al. (2019) | |
| ↑ Cell apoptosis (annexin V) | ||||||
| JWH-015 | 20 μM (1 h) | AM630 (500 nM) | ↓ CXCL12-induced chemotaxis | ↑ CXCL12-induced p-ERK1/2 | Ghosh et al. (2006) | |
| ↓ Transendothelial migration | Migration not inhibited by the MEK-1 inhibitor PD 98,059 | |||||
| ↓ PMA-induced MMP9 | ||||||
| 250 nM (2 h) | AM630 (500 nM) | ↓ anti-CD3/anti-CD28-induced IL-2 production | - ↓ p-ERK1/2 | Borner et al. (2009) | ||
| - ↑ p-Lck | ||||||
| - ↓ cAMP levels | ||||||
| - Increased cAMP levels were inhibited by PTX | ||||||
| LV50 | 10 μM (4–72 h) | SR144528 (1 μM) | ↓ T cell proliferation | Capozzi et al. (2018) | ||
| ↑ Apoptosis | ||||||
| Δ9-THC | 1–5 μM (1–2 h) | SR144528 (2 μM) | ↓ Cell viability | Herrera et al. (2006) | ||
| ↑ Apoptosis (Annexin 5) | ||||||
| ↑ Ceramide levels | ||||||
| Activation of caspase 8 at a post-mitochondrial level | ||||||
| Monocytes | ||||||
| Blood | 2-AG | 10 nM–10 μM (4 h) | SR144528 (1 μM) | ↑ Migration (chemotaxis toward 2-AG) | Kishimoto et al. (2003) | |
| (E)-β-caryophyllene | 500 nM (18 h) | AM630 (5 μM) | ↓ LPS-induced IL-1β and TNFα | ↓ LPS-induced p-ERK1/2 and p-JNK1/2 | Gertsch et al. (2008) | |
| JWH-015 | 5–20 μM (60 min) | SR144528 (1 μM) | ↓ CCL2- and CCL3-induced migration | - Inhibited by PI3K and the MEK-1 inhibitors | Montecucco et al. (2008) | |
| ↓ CCR2 and CCR1 mRNA expression | - Not inhibited by the p38 inhibitor SB-203580 | |||||
| ↓ IFNγ-induced ICAM-1 induction | ||||||
| 1–10 μM (20 min) | - | ↓ IL-1β | Rizzo et al. (2019) | |||
| JWH-133 | 1 μM (18 h) | SR144528 (1 μM) | - | ↑ p-ERK1/2 | Gertsch et al. (2008) | |
| 0.1–10 μM (days 4, 7 and 10) | - | ↓ HIV-1 viral infection during differentiation in monocyte derived macrophages | Williams et al. (2014) | |||
| U937 cells | 2-AG | 1 μM (5 min) | SR144528 (3 μM) | ↑ Adhesion to fibronectin | Gokoh et al. (2005a) | |
| CP 55,940 | 1 nM–1 μM (2 h) | SR144528 (1 μM) | ↓ HIV-1 transactivating protein-enhanced adhesion of cells to extracellular matrix protein, such as collagen IV and laminin | Raborn et al. (2014) | ||
| WIN 55,212–2 | 1–10 μM (2 h) | AM630 (1 μM) | ↓ Adhesion to HUVECs | Zhao et al. (2010) | ||
| Mast cells | ||||||
| Endometrial | JWH-015 | 10−8–10−6 M (2 h) | - | ↓ Calcium ionophore A23187-induced degranulation | Iuvone et al. (2008) | |
| Macrophages | ||||||
| Monocyte-derived macrophages (healthy subjects) | JWH-015 | 50 nM (30 min) | SR144528 (50 nM–0.1 μM) | ↓ oxLDL-induced CD36 | Chiurchiu et al. (2014) | |
| ↓ oxLDL-induced TNF-α, IL-12 and IL-10 | ||||||
| Lenabasum | 0.1–30 μM (Day 0, 3, and 6) | - | No effect | Tarique et al. (2020) | ||
| Monocyte-derived macrophages (patients with cystic fibrosis) | Lenabasum | 0.1–30 μM (Day 0, 3, and 6) | - | ↓ Macrophage polarization into pro-inflammatory M1 phenotype | Tarique et al. (2020) | |
| ↓ IL-8 and TNF-α secretion | ||||||
| Lung | JWH-133 | 1 μM (10 min) | AM630 (0.5 μM) | ↓ LPS-induced VEGF-A and VEGF-C | ↑ p-ERK1/2 | Staiano et al. (2016) |
| ↓ LPS-induced IL-6 | ||||||
| HL-60-derived macrophage | 2-AG | 1 μM (1 min) | SR144528 (1 μM) | Induce morphological changes such as the extension of pseudopods | - Inhibited by PTX (Gi/0-dependant) | Gokoh et al. (2005b) |
| ↑ Actin polymerization | - Inhibited by selective chelating agent for intracellular free Ca2+ BAPTA-AM | |||||
| - Inhibited by the PI3K inhibitor wortmannin -Not inhibited by the tyrosine kinase inhibitor herbimycin, the MEK-1 inhibitor PD 98,059 or the PKC inhibitor Ro-31–8220 | ||||||
| THP-1-derived macrophage M2 | JWH-015 | 1–5 μM (12 h) | - | ↓ Migration of A549 cells | ↓ p-ERK1/2 and p-STAT3 | Ravi et al. (2016) |
| Dendritic cells | ||||||
| Myeloid | AEA | 2.5 μM (4 h) | SR144528 (1 μM) | ↓ R848-induced TNF-α, IL-12p40, IL-6 | Chiurchiu et al. (2013) | |
| JWH-015 | 1 μM (4 h) | SR144528 (1 μM) | ↓ R848-induced TNF-α, IL-12p40, IL-6 | Chiurchiu et al. (2013) | ||
| Plasmacytoid (healthy subjects) | AEA | 2.5 μM (4 h) | SR144528 (1 μM) | ↓ R848-induced TNF-α, IFN-α | Chiurchiu et al. (2013) | |
| 2-AG | 10 μM (18 h) | SR144528 (1 μM) | ↓ CpGA-induced IFNα | Rahaman et al. (2019) | ||
| ↓ TLR9 activation | ||||||
| JWH-015 | 1 μM (4 h) | SR144528 (1 μM) | ↓ R848-induced TNF-α and IFN-α | Chiurchiu et al. (2013) | ||
| 0.01–1 μM (5 h) | - | ↓ CpG-induced IFNα and TNFα | ↓ p-IRF7, p-TBK1, p-NF-κB and p-IKKγ | Henriquez et al. (2019) | ||
| JWH-133 | 0.001–0.1 μM (5 h) | - | ↓ CpG-induced IFNα and TNFα | ↓ p-IRF7, p-TBK1, p-NF-κB and p-IKKγ | Henriquez et al. (2019) | |
| Plasmacytoid (patient with multiple sclerosis) | AEA | 2.5 μM (4 h) | SR144528 (1 μM) | No effect | Chiurchiu et al. (2013) | |
| JWH-015 | 1 μM (4 h) | SR144528 (1 μM) | No effect | Chiurchiu et al. (2013) | ||
CB2-mediated effects on human leukocytes and related human cell lines.
Human Eosinophils
Eosinophils participate in innate immunity against parasites and in the development/persistence of diverse inflammatory responses, notably allergies and asthma. Studies involving human eosinophils and CB receptors are scarce. Their treatment with either the endocannabinoid 2-AG and/or CB2 receptor agonists stimulated their migration or potentiated their migration toward other chemoattractants (Oka et al., 2004; Kishimoto et al., 2006; Larose et al., 2014; Frei et al., 2016). Importantly, these effects were prevented by the CB2 receptor antagonists AM630 and/or SR144528. Consistent with a CB2-mediated increased in eosinophil migration, cannabis use has been linked to some cases of acute eosinophilic pneumonia, although no demonstration has proven that this involved the CB2 receptor (Sauvaget et al., 2010; Liebling and Siu 2013; Natarajan et al., 2013; Ocal et al., 2016; Mull et al., 2020). Interestingly, while JWH-133 led to a moderate chemotactic response in human eosinophils, it had no effect on mouse eosinophils (Frei et al., 2016). Altogether, the current data support that the CB2 receptor stimulates eosinophil migration. This could eventually lead to increased parasitic defenses but also to a worsening of eosinophils-related inflammatory diseases.
Human B Lymphocytes
B lymphocytes maturation and differentiation are complex processes. Following their activation, naïve cells (spleen marginal zone) proliferate and differentiate into short-lived plasma cells, while cells from the follicles undergo massive proliferation and form germinal centers, where long-lived plasma and memory cells are formed (Basu et al., 2013). Very little is known about the role of the CB2 receptor in human B lymphocytes but their treatment with CP 55,940 increased their proliferation, a phenomenon blocked by SR144528 (Carayon et al., 1998). In mice, activation of the CB2 receptor has been associated with B lymphocyte differentiation, migration, proliferation and antibody class switching (Jorda et al., 2002; Tanikawa et al., 2007; Agudelo et al., 2008), suggesting the receptor is part of the B lymphocytes immune programing, playing an important role in B lymphocyte repertoire formation (Pereira et al., 2009).
Human Neutrophils
Neutrophils are first responders of the innate immune system, playing crucial roles in acute inflammatory responses and host defense. They employ several strategies to fight microbes, including the phagocytosis and killing of pathogens with the help of their granule content. Studies showing a CB
2-receptor-mediated effect of human neutrophils were not conclusive and contaminating eosinophils in neutrophil preparations might have caused a red herring situation, eosinophils being responsible for most of the CB
2receptor signal/effects (
Figure 1and
Expression of the CB1and CB2Receptors by Human Blood Leukocytes). In fact, numerous studies indicated that endocannabinoids as well as selective and non-selective CB
2receptor agonists do not diminish human neutrophil functions (migration, superoxide generation and degranulation)
viathe CB
2receptor and when they display an inhibitory effect on their functional responses it is mostly related to a mechanism distinct from the CB
1and CB
2receptors (
Deusch et al., 2003;
Kraft et al., 2004;
Oka et al., 2004;
McHugh et al., 2008;
Chouinard et al., 2011;
Montecucco et al., 2012;
Zhou et al., 2020), which is consistent with their lack/very low expression of the CB
2receptor. In contrast, JWH-133 inhibited the release of VEGF-A but not CXCL8 from LPS-stimulated human neutrophils, a phenomenon prevented by the CB
2receptor antagonist AM630 (
Braile et al., 2021).
• In vivo studies indicated that mouse neutrophils are more responsive to CB2 receptor activation than human neutrophils. As such, Cnr2−/− mice models reported increased neutrophil numbers at inflammatory sites (Alferink et al., 2016; Kapellos et al., 2017; Kapellos et al., 2019). Accordingly, CB2 activation by selective agonists suppressed neutrophil recruitment to the inflammation site (Horvath et al., 2012; Andrade-Silva et al., 2016; Wang et al., 2016; Parlar et al., 2018; Kapellos et al., 2019). However, it is not clear whether the reported evidence is a matter of mouse neutrophil responsiveness or of indirect CB2-dependent effects mediated by other cells (Kraft and Kress 2005). At this point, we cannot exclude that a CB2-dependent mechanism prevents neutrophil recruitment into by impairing their transmigration into the tissues and by affecting other cells (e.g., endothelial cells) as proposed earlier (Nilsson et al., 2006).
Human T Lymphocytes
Cytotoxic CD8 T lymphocytes are responsible for the elimination of invading/dysfunctional cells while CD4 T lymphocytes produce a myriad of inflammatory mediators and are referred to as helper lymphocytes (Th). Although CB2 receptor expression was barely detected in circulating T lymphocytes (Figure 1), several studies reported that CB2 receptor expression is increased in activated T lymphocytes and that its activation decreases their proliferation (Borner et al., 2009; Cencioni et al., 2010; Capozzi et al., 2018). This is accompanied with decreased IL-2 production and increased apoptosis (Herrera et al., 2006; Borner et al., 2009; Cencioni et al., 2010; Capozzi et al., 2018; Huang et al., 2019). Interestingly, CB2 receptor activation seems to exert divergent effects depending on the T lymphocyte subtype with the tendency to decrease human Th1 and Th17 functions, while promoting those of Th2. For instance, Δ9-THC decreased in a CB2-dependant manner the percentage of human T lymphocytes expressing IFN-γ, and intracellular levels of IFN-γ per cells (Th1), while increasing levels of IL-4 and IL-5 (Th2) (Yuan et al., 2002). Accordingly, a decrease in IL-17 levels was found in JWH-015-treated T lymphocytes (Cencioni et al., 2010). Finally, the CB2 agonist Lenabasum reduced TNF-α in both CD8 and CD4 T lymphocytes (Th1). The treatment also decreased IL-17 levels (Th17) as well as Th1 and Th17 respective signature transcription factors T-bet and RORγt (Tiberi et al., 2021).
Human Monocytes
Blood monocytes migrate into tissues where they differentiate into macrophages or convert into non-classical monocytes (Guilliams et al., 2018). 2-AG is a CB2-dependant human monocyte chemoattractant (Kishimoto et al., 2003) and induces the adhesion of human monocytic U937 cells to fibronectin (Gokoh et al., 2005a). However, JWH-015 decreased the CCL2-and CCL3-induced migration of human monocytes by decreasing their receptors’ expression (Montecucco et al., 2008). JWH-015 also reduces human monocyte differentiation and U937 cells adhesion to extracellular matrix proteins, both induced by HIV-1 (Raborn et al., 2014; Williams et al., 2014). Finally, CB2 receptor engagement in human monocytes was shown to decrease the LPS-induced IL-1β and IL-6 production (Gu et al., 2019; Rizzo et al., 2019).
Human Macrophages
Macrophages are resident cells that are remarkably versatile, exerting important roles in development, homeostasis, tissue repair and immunity. The endocannabinoid 2-AG was found to induce shape changes of HL-60-derived macrophages in a CB2-depandent manner (Gokoh et al., 2005b). Additionally, CB2 receptor activation with JWH-015 or JWH-133 decreased the LPS-induced VEGF-A, VEGF-C IL-6 release, as well as the oxLDL-induced release of TNF-α, IL-12 and IL-10 (Chiurchiu et al., 2014; Staiano et al., 2016). In mice, the CB2 receptor was shown to switch the polarization of M1 macrophage into M2 macrophage (Duerr et al., 2014; Denaes et al., 2016; Du et al., 2018). Such a phenomenon has been partially observed in humans by Tarique et al. who showed that Lenabasum decreased the polarization (M1) of monocyte-derived macrophage obtained from cystic fibrosis patients (Tarique et al., 2020).
Human Mast Cells
Mast cells are strategically located at the interface with the external environment, acting as key initiators of local inflammatory responses (Elieh Ali Komi et al., 2020). The first evidence that they could be regulated by the CB2 receptor came from the rat basophilic leukemia cell line (RBL-2H3) expressing the CB2 receptor (Facci et al., 1995). However, while the authors showed that N-palmitoyl-ethanolamine (PEA) inhibited serotonin release AEA did not. However, PEA interacts with PPARα (Lo Verme et al., 2005) and its initial effects are likely linked to PPARα. In humans, the treatment of isolated mast cells with JWH-015 decreased their degranulation in vitro (Iuvone et al., 2008).
Human Dendritic Cells
Dendritic cells are sentinels of the immune system bridging the innate and adaptive immunity by ingesting pathogens and transporting antigens to lymphoid tissues. Stimulation of CB2 receptor with CB2 receptor agonists reduced their cytokine production. Indeed, AEA and JWH-015 decreased R848-induced levels of TNF-α, IL-12p40 and IL-6 by myeloid dendritic cells while AEA, 2-AG, JWH-015 and JWH-133 decreased levels of R848-and/or CpG-induced IFN-α by plasmacytoid dendritic cells by a mechanisms involving NF-κB and IKKγ signalization (Chiurchiu et al., 2013; Henriquez et al., 2019; Rahaman et al., 2019).
Conclusion
It is becoming clear that the CB2 receptor plays important roles in the regulation of several inflammatory processes. However, while the first studies investigating the role of this receptor in mice led to the concept that its function was mainly anti-inflammatory, new evidence is challenging this concept, notably in allergic diseases, which usually involve cells such as eosinophils and B lymphocytes, whose functional responses to CB2 receptor activation simulates them, in human-based studies. Moreover, the scarcity of human studies investigating the CB2 receptor makes our understanding of the latter difficult at this point and underscores the urgency of performing additional work involving human samples/cells to deepen our understanding of CB2-receptor-driven inflammatory responses and establish to what extent we can translate findings from experimental models to the clinic. It is thus urgent to further characterize the functions of the CB2 receptor in human leukocytes and inflammatory diseases.
Statements
Data availability statement
The original contributions presented in the study are included in the article, further inquiries can be directed to the corresponding author.
Ethics statement
The studies involving human participants were reviewed and approved by the Comité d’éthique de la recherche de l’Institut universitaire de cardiologie et de pneumologie de Québec. The participants provided their written informed consent to participate in this study.
Author contributions
Conceptualization: MS, VR, VD, and NF; Investigation: MS and VR; Data curation—formal analysis: MS, VR, and NF; Writing—original draft: MS and NF; Writing—review, editing, and revision: MS, VR, VD, and NF.
Funding
This work was supported by grants to NF from The Natural Sciences and Engineering Research Council of Canada (RGPIN-2021-03777) and to VD from the Canada Excellence Research Chair on the Microbiome-Endocannabinoidome Axis in Metabolic Health. VR was supported by a post-doctoral award from the Québec Heart and Lung Institute Foundation.
Acknowledgments
We would like to thank Andréanne Côté and Annie Roy for providing the blood samples.
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
AgudeloM.NewtonC.WidenR.SherwoodT.NongL.FriedmanH.et al (2008). Cannabinoid Receptor 2 (CB2) Mediates Immunoglobulin Class Switching from IgM to IgE in Cultures of Murine-Purified B Lymphocytes. J. Neuroimmune Pharmacol.3 (1), 35–42. 10.1007/s11481-007-9088-9
2
AlferinkJ.SpechtS.ArendsH.SchumakB.SchmidtK.RulandC.et al (2016). Cannabinoid Receptor 2 Modulates Susceptibility to Experimental Cerebral Malaria through a CCL17-dependent Mechanism. J. Biol. Chem.291 (37), 19517–19531. 10.1074/jbc.M116.746594
3
Andrade-SilvaM.CorreaL. B.CandéaA. L.Cavalher-MachadoS. C.BarbosaH. S.RosasE. C.et al (2016). The Cannabinoid 2 Receptor Agonist β-caryophyllene Modulates the Inflammatory Reaction Induced by Mycobacterium Bovis BCG by Inhibiting Neutrophil Migration. Inflamm. Res.65 (11), 869–879. 10.1007/s00011-016-0969-3
4
BasuS.RayA.DittelB. N. (2013). Cannabinoid Receptor 2 (CB2) Plays a Role in the Generation of Germinal Center and Memory B Cells, but Not in the Production of Antigen-Specific IgG and IgM, in Response to T-dependent Antigens. PLoS One8 (6), e67587. 10.1371/journal.pone.0067587
5
BörnerC.SmidaM.HölltV.SchravenB.KrausJ. (2009). Cannabinoid Receptor Type 1- and 2-mediated Increase in Cyclic AMP Inhibits T Cell Receptor-Triggered Signaling. J. Biol. Chem.284 (51), 35450–35460. 10.1074/jbc.M109.006338
6
BozkurtT. E.KayaY.Durlu-KandilciN. T.OnderS.Sahin-ErdemliI. (2016). The Effect of Cannabinoids on Dinitrofluorobenzene-Induced Experimental Asthma in Mice. Respir. Physiol. Neurobiol.231, 7–13. 10.1016/j.resp.2016.05.012
7
BraileM.CristinzianoL.MarcellaS.VarricchiG.MaroneG.ModestinoL.et al (2021). LPS-mediated Neutrophil VEGF-A Release Is Modulated by Cannabinoid Receptor Activation. J. Leukoc. Biol.109 (3), 621–631. 10.1002/JLB.3A0520-187R
8
BrownS. M.Wager-MillerJ.MackieK. (2002). Cloning and Molecular Characterization of the Rat CB2 Cannabinoid Receptor. Biochim. Biophys. Acta1576 (3), 255–264. 10.1016/s0167-4781(02)00341-x
9
CakirM.TekinS.DoganyigitZ.CakanP.KaymakE. (2019). The Protective Effect of Cannabinoid Type 2 Receptor Activation on Renal Ischemia-Reperfusion Injury. Mol. Cel Biochem462 (1-2), 123–132.
10
CapozziA.MatteiV.MartellucciS.ManganelliV.SaccomanniG.GarofaloT.et al (2018). Anti-proliferative Properties and Proapoptotic Function of New CB2 Selective Cannabinoid Receptor Agonist in Jurkat Leukemia Cells. Int. J. Mol. Sci.19 (7), 1958. 10.3390/ijms19071958
11
CarayonP.MarchandJ.DussossoyD.DerocqJ. M.JbiloO.BordA.et al (1998). Modulation and Functional Involvement of CB2 Peripheral Cannabinoid Receptors during B-Cell Differentiation. Blood92 (10), 3605–3615. 10.1182/blood.v92.10.3605.422k05_3605_3615
12
CastanedaJ. T.HaruiA.KiertscherS. M.RothJ. D.RothM. D. (2013). Differential Expression of Intracellular and Extracellular CB(2) Cannabinoid Receptor Protein by Human Peripheral Blood Leukocytes. J. Neuroimmune Pharmacol.8 (1), 323–332. 10.1007/s11481-012-9430-8
13
CencioniM. T.ChiurchiùV.CatanzaroG.BorsellinoG.BernardiG.BattistiniL.et al (2010). Anandamide Suppresses Proliferation and Cytokine Release from Primary Human T-Lymphocytes Mainly via CB2 Receptors. PLoS One5 (1), e8688. 10.1371/journal.pone.0008688
14
ChiurchiùV.CencioniM. T.BisicchiaE.De BardiM.GasperiniC.BorsellinoG.et al (2013). Distinct Modulation of Human Myeloid and Plasmacytoid Dendritic Cells by Anandamide in Multiple Sclerosis. Ann. Neurol.73 (5), 626–636. 10.1002/ana.23875
15
ChiurchiùV.LanutiM.CatanzaroG.FezzaF.RapinoC.MaccarroneM. (2014). Detailed Characterization of the Endocannabinoid System in Human Macrophages and Foam Cells, and Anti-inflammatory Role of Type-2 Cannabinoid Receptor. Atherosclerosis233 (1), 55–63. 10.1016/j.atherosclerosis.2013.12.042
16
ChouinardF.LefebvreJ. S.NavarroP.BouchardL.FerlandC.Lalancette-HébertM.et al (2011). The Endocannabinoid 2-Arachidonoyl-Glycerol Activates Human Neutrophils: Critical Role of its Hydrolysis and de novo Leukotriene B4 Biosynthesis. J. Immunol.186 (5), 3188–3196. 10.4049/jimmunol.1002853
17
ChouinardF.TurcotteC.GuanX.LaroseM. C.PoirierS.BouchardL.et al (2013). 2-Arachidonoyl-glycerol- and Arachidonic Acid-Stimulated Neutrophils Release Antimicrobial Effectors against E. coli, S. aureus, HSV-1, and RSV. J. Leukoc. Biol.93 (2), 267–276. 10.1189/jlb.0412200
18
CoopmanK.SmithL. D.WrightK. L.WardS. G. (2007). Temporal Variation in CB2R Levels Following T Lymphocyte Activation: Evidence that Cannabinoids Modulate CXCL12-Induced Chemotaxis. Int. Immunopharmacol7 (3), 360–371. 10.1016/j.intimp.2006.11.008
19
CorradoA.BattleM.WiseS. K.LeeF. E.GuidotD. M.DelGaudioJ. M.et al (2018). Endocannabinoid Receptor CB2R Is Significantly Expressed in Aspirin-Exacerbated Respiratory Disease: a Pilot Study. Int. Forum Allergy Rhinol8 (10), 1184–1189. 10.1002/alr.22163
20
CostantinoC. M.GuptaA.YewdallA. W.DaleB. M.DeviL. A.ChenB. K. (2012). Cannabinoid Receptor 2-mediated Attenuation of CXCR4-Tropic HIV Infection in Primary CD4+ T Cells. PLoS One7 (3), e33961. 10.1371/journal.pone.0033961
21
DenaësT.LodderJ.ChobertM. N.RuizI.PawlotskyJ. M.LotersztajnS.et al (2016). The Cannabinoid Receptor 2 Protects against Alcoholic Liver Disease via a Macrophage Autophagy-dependent Pathway. Sci. Rep.6, 28806. 10.1038/srep28806
22
DeuschE.KraftB.NahlikG.WeiglL.HoheneggerM.KressH. G. (2003). No Evidence for Direct Modulatory Effects of delta 9-tetrahydrocannabinol on Human Polymorphonuclear Leukocytes. J. Neuroimmunol141 (1-2), 99–103. 10.1016/s0165-5728(03)00259-5
23
DevaneW. A.DysarzF. A.3rdJohnsonM. R.MelvinL. S.HowlettA. C. (1988). Determination and Characterization of a Cannabinoid Receptor in Rat Brain. Mol. Pharmacol.34 (5), 605–613.
24
Di MarzoV.MelckD.BisognoT.De PetrocellisL. (1998). Endocannabinoids: Endogenous Cannabinoid Receptor Ligands with Neuromodulatory Action. Trends Neurosci.21 (12), 521–528. 10.1016/s0166-2236(98)01283-1
25
Di MarzoV. (2018). New Approaches and Challenges to Targeting the Endocannabinoid System. Nat. Rev. Drug Discov.17 (9), 623–639. 10.1038/nrd.2018.115
26
DoY.McKallipR. J.NagarkattiM.NagarkattiP. S. (2004). Activation through Cannabinoid Receptors 1 and 2 on Dendritic Cells Triggers NF-kappaB-dependent Apoptosis: Novel Role for Endogenous and Exogenous Cannabinoids in Immunoregulation. J. Immunol.173 (4), 2373–2382. 10.4049/jimmunol.173.4.2373
27
DothelG.ChangL.ShihW.BarbaroM. R.CremonC.StanghelliniV.et al (2019). Micro-Opioid Receptor, Beta-Endorphin, and Cannabinoid Receptor-2 Are Increased in the Colonic Mucosa of Irritable Bowel Syndrome Patients. Neurogastroenterol Motil.31 (11), e13688. 10.1111/nmo.13688
28
DuY.RenP.WangQ.JiangS. K.ZhangM.LiJ. Y.et al (2018). Cannabinoid 2 Receptor Attenuates Inflammation during Skin Wound Healing by Inhibiting M1 Macrophages rather Than Activating M2 Macrophages. J. Inflamm. (Lond)15, 25. 10.1186/s12950-018-0201-z
29
DuerrG. D.HeinemannJ. C.SuchanG.KolobaraE.WenzelD.GeisenC.et al (2014). The Endocannabinoid-CB2 Receptor axis Protects the Ischemic Heart at the Early Stage of Cardiomyopathy. Basic Res. Cardiol.109 (4), 425. 10.1007/s00395-014-0425-x
30
Elieh Ali KomiD.WöhrlS. L.BieloryL. (2020). Mast Cell Biology at Molecular Level: a Comprehensive Review. Clin. Rev. Allergy Immunol.58 (3), 342–365. 10.1007/s12016-019-08769-2
31
Ellert-MiklaszewskaA.GrajkowskaW.GabrusiewiczK.KaminskaB.KonarskaL. (2007). Distinctive Pattern of Cannabinoid Receptor Type II (CB2) Expression in Adult and Pediatric Brain Tumors. Brain Res.1137 (1), 161–169. 10.1016/j.brainres.2006.12.060
32
FacciL.Dal TosoR.RomanelloS.BurianiA.SkaperS. D.LeonA. (1995). Mast Cells Express a Peripheral Cannabinoid Receptor with Differential Sensitivity to Anandamide and Palmitoylethanolamide. Proc. Natl. Acad. Sci. U S A.92 (8), 3376–3380. 10.1073/pnas.92.8.3376
33
FantauzziM. F.AguiarJ. A.TremblayB. J.MansfieldM. J.YanagiharaT.ChandiramohanA.et al (2020). Expression of Endocannabinoid System Components in Human Airway Epithelial Cells: Impact of Sex and Chronic Respiratory Disease Status. ERJ Open Res.6 (4). 10.1183/23120541.00128-2020
34
FengR.MilcarekC. A.XieX. Q. (2014). Antagonism of Cannabinoid Receptor 2 Pathway Suppresses IL-6-induced Immunoglobulin IgM Secretion. BMC Pharmacol. Toxicol.15, 30. 10.1186/2050-6511-15-30
35
FerriniM. E.HongS.StierleA.StierleD.StellaN.RobertsK.et al (2017). CB2 Receptors Regulate Natural Killer Cells that Limit Allergic Airway Inflammation in a Murine Model of Asthma. Allergy72 (6), 937–947. 10.1111/all.13107
36
FreiR. B.LuschnigP.ParzmairG. P.PeinhauptM.SchranzS.FaulandA.et al (2016). Cannabinoid Receptor 2 Augments Eosinophil Responsiveness and Aggravates Allergen-Induced Pulmonary Inflammation in Mice. Allergy71 (7), 944–956. 10.1111/all.12858
37
Freundt-RevillaJ.HeinrichF.ZoernerA.GesellF.BeyerbachM.ShamirM.et al (2018). The Endocannabinoid System in Canine Steroid-Responsive Meningitis-Arteritis and Intraspinal Spirocercosis. PLoS One13 (2), e0187197. 10.1371/journal.pone.0187197
38
FukudaH.AbeT.YoshiharaS. (2010). The Cannabinoid Receptor Agonist WIN 55,212-2 Inhibits Antigen-Induced Plasma Extravasation in guinea Pig Airways. Int. Arch. Allergy Immunol.152 (3), 295–300. 10.1159/000283042
39
GaliègueS.MaryS.MarchandJ.DussossoyD.CarrièreD.CarayonP.et al (1995). Expression of central and Peripheral Cannabinoid Receptors in Human Immune Tissues and Leukocyte Subpopulations. Eur. J. Biochem.232 (1), 54–61. 10.1111/j.1432-1033.1995.tb20780.x
40
GertschJ.LeontiM.RadunerS.RaczI.ChenJ. Z.XieX. Q.et al (2008). Beta-caryophyllene Is a Dietary Cannabinoid. Proc. Natl. Acad. Sci. U S A.105 (26), 9099–9104. 10.1073/pnas.0803601105
41
GhoshS.PreetA.GroopmanJ. E.GanjuR. K. (2006). Cannabinoid Receptor CB2 Modulates the CXCL12/CXCR4-Mediated Chemotaxis of T Lymphocytes. Mol. Immunol.43 (14), 2169–2179. 10.1016/j.molimm.2006.01.005
42
GokohM.KishimotoS.OkaS.MetaniY.SugiuraT. (2005a). 2-Arachidonoylglycerol, an Endogenous Cannabinoid Receptor Ligand, Enhances the Adhesion of HL-60 Cells Differentiated into Macrophage-like Cells and Human Peripheral Blood Monocytes. FEBS Lett.579 (28), 6473–6478. 10.1016/j.febslet.2005.10.030
43
GokohM.KishimotoS.OkaS.MoriM.WakuK.IshimaY.et al (2005b). 2-arachidonoylglycerol, an Endogenous Cannabinoid Receptor Ligand, Induces Rapid Actin Polymerization in HL-60 Cells Differentiated into Macrophage-like Cells. Biochem. J.386 (Pt 3), 583–589. 10.1042/BJ20041163
44
GrahamE. S.AngelC. E.SchwarczL. E.DunbarP. R.GlassM. (2010). Detailed Characterisation of CB2 Receptor Protein Expression in Peripheral Blood Immune Cells from Healthy Human Volunteers Using Flow Cytometry. Int. J. Immunopathol Pharmacol.23 (1), 25–34. 10.1177/039463201002300103
45
GrecoR.DemartiniC.ZanaboniA.TumeleroE.ElisaC.PersicoA.et al (2021). Characterization of CB2 Receptor Expression in Peripheral Blood Monocytes of Acute Ischemic Stroke Patients. Transl Stroke Res.12 (4), 550–558. 10.1007/s12975-020-00851-8
46
GuZ.SinghS.NiyogiR. G.LamontG. J.WangH.LamontR. J.et al (2019). Marijuana-Derived Cannabinoids Trigger a CB2/PI3K Axis of Suppression of the Innate Response to Oral Pathogens. Front. Immunol.10, 2288. 10.3389/fimmu.2019.02288
47
GuilliamsM.MildnerA.YonaS. (2018). Developmental and Functional Heterogeneity of Monocytes. Immunity49 (4), 595–613. 10.1016/j.immuni.2018.10.005
48
GustafssonK.ChristenssonB.SanderB.FlygareJ. (2006). Cannabinoid Receptor-Mediated Apoptosis Induced by R(+)-methanandamide and Win55,212-2 Is Associated with Ceramide Accumulation and P38 Activation in Mantle Cell Lymphoma. Mol. Pharmacol.70 (5), 1612–1620. 10.1124/mol.106.025981
49
HarunaT.SogaM.MoriokaY.ImuraK.FurueY.YamamotoM.et al (2017). The Inhibitory Effect of S-777469, a Cannabinoid Type 2 Receptor Agonist, on Skin Inflammation in Mice. Pharmacology99 (5-6), 259–267. 10.1159/000455916
50
HenriquezJ. E.CrawfordR. B.KaminskiN. E. (2019). Suppression of CpG-ODN-Mediated IFNα and TNFα Response in Human Plasmacytoid Dendritic Cells (pDC) by Cannabinoid Receptor 2 (CB2)-specific Agonists. Toxicol. Appl. Pharmacol.369, 82–89. 10.1016/j.taap.2019.02.013
51
HerreraB.CarracedoA.Diez-ZaeraM.Gómez del PulgarT.GuzmánM. G.VelascoG. (2006). The CB2 Cannabinoid Receptor Signals Apoptosis via Ceramide-dependent Activation of the Mitochondrial Intrinsic Pathway. Exp. Cel Res312 (11), 2121–2131. 10.1016/j.yexcr.2006.03.009
52
HorváthB.MagidL.MukhopadhyayP.BátkaiS.RajeshM.ParkO.et al (2012). A New Cannabinoid CB2 Receptor Agonist HU-910 Attenuates Oxidative Stress, Inflammation and Cell Death Associated with Hepatic Ischaemia/reperfusion Injury. Br. J. Pharmacol.165 (8), 2462–2478. 10.1111/j.1476-5381.2011.01381.x
53
HowlettA. C.AboodM. E. (2017). CB1 and CB2 Receptor Pharmacology. Adv. Pharmacol.80, 169–206. 10.1016/bs.apha.2017.03.007
54
HuangZ. B.ZhengY. X.LiN.CaiS. L.HuangY.WangJ.et al (2019). Protective Effects of Specific Cannabinoid Receptor 2 Agonist GW405833 on Concanavalin A-Induced Acute Liver Injury in Mice. Acta Pharmacol. Sin40 (11), 1404–1411. 10.1038/s41401-019-0213-0
55
HurrellB. P.HelouD. G.Shafiei-JahaniP.HowardE.PainterJ. D.QuachC.et al (2021). Cannabinoid Receptor II Engagement Promotes ILC2 Expansion and Enhances ILC2-dependent Airway Hyperreactivity. J. Allergy Clin. Immunol..
56
IuvoneT.De FilippisD.Di Spiezio SardoA.D'AmicoA.SimonettiS.SpariceS.et al (2008). Selective CB2 Up-Regulation in Women Affected by Endometrial Inflammation. J. Cel Mol Med12 (2), 661–670. 10.1111/j.1582-4934.2007.00085.x
57
JordàM. A.VerbakelS. E.ValkP. J.Vankan-BerkhoudtY. V.MaccarroneM.Finazzi-AgròA.et al (2002). Hematopoietic Cells Expressing the Peripheral Cannabinoid Receptor Migrate in Response to the Endocannabinoid 2-arachidonoylglycerol. Blood99 (8), 2786–2793. 10.1182/blood.v99.8.2786
58
KapellosT. S.RecioC.GreavesD. R.IqbalA. J. (20172017). Cannabinoid Receptor 2 Modulates Neutrophil Recruitment in a Murine Model of Endotoxemia. Mediators Inflamm.2017, 4315412. 10.1155/2017/4315412
59
KapellosT. S.TaylorL.FeuerbornA.ValarisS.HussainM. T.RaingerG. E.et al (2019). Cannabinoid Receptor 2 Deficiency Exacerbates Inflammation and Neutrophil Recruitment. FASEB J.33 (5), 6154–6167. 10.1096/fj.201802524R
60
KishimotoS.GokohM.OkaS.MuramatsuM.KajiwaraT.WakuK.et al (2003). 2-arachidonoylglycerol Induces the Migration of HL-60 Cells Differentiated into Macrophage-like Cells and Human Peripheral Blood Monocytes through the Cannabinoid CB2 Receptor-dependent Mechanism. J. Biol. Chem.278 (27), 24469–24475. 10.1074/jbc.M301359200
61
KishimotoS.OkaS.GokohM.SugiuraT. (2006). Chemotaxis of Human Peripheral Blood Eosinophils to 2-arachidonoylglycerol: Comparison with Other Eosinophil Chemoattractants. Int. Arch. Allergy Immunol.140 Suppl 1 (Suppl. 1), 3–7. 10.1159/000092704
62
KraftB.KressH. G. (2005). Indirect CB2 Receptor and Mediator-dependent Stimulation of Human Whole-Blood Neutrophils by Exogenous and Endogenous Cannabinoids. J. Pharmacol. Exp. Ther.315 (2), 641–647. 10.1124/jpet.105.084269
63
KraftB.WintersbergerW.KressH. G. (2004). Cannabinoid Receptor-independent Suppression of the Superoxide Generation of Human Neutrophils (PMN) by CP55 940, but Not by Anandamide. Life Sci.75 (8), 969–977. 10.1016/j.lfs.2004.02.007
64
KuriharaR.TohyamaY.MatsusakaS.NaruseH.KinoshitaE.TsujiokaT.et al (2006). Effects of Peripheral Cannabinoid Receptor Ligands on Motility and Polarization in Neutrophil-like HL60 Cells and Human Neutrophils. J. Biol. Chem.281 (18), 12908–12918. 10.1074/jbc.M510871200
65
LaroseM. C.ArchambaultA. S.ProvostV.LavioletteM.FlamandN. (2017). Regulation of Eosinophil and Group 2 Innate Lymphoid Cell Trafficking in Asthma. Front. Med. (Lausanne)4, 136. 10.3389/fmed.2017.00136
66
LaroseM. C.TurcotteC.ChouinardF.FerlandC.MartinC.ProvostV.et al (2014). Mechanisms of Human Eosinophil Migration Induced by the Combination of IL-5 and the Endocannabinoid 2-Arachidonoyl-Glycerol. J. Allergy Clin. Immunol.133 (5), 1480–1483. 10.1016/j.jaci.2013.12.1081
67
LeeS. F.NewtonC.WidenR.FriedmanH.KleinT. W. (2001). Downregulation of Cannabinoid Receptor 2 (CB2) Messenger RNA Expression during In Vitro Stimulation of Murine Splenocytes with Lipopolysaccharide. Adv. Exp. Med. Biol.493, 223–228. 10.1007/0-306-47611-8_26
68
LieblingP. D.SiuS. (2013). A Novel Cause of Eosinophilic Pneumonia: Recreational Marijuana Exposure. J. Bronchology Interv. Pulmonol20 (2), 183–185. 10.1097/LBR.0b013e31828caa0d
69
Lo VermeJ.FuJ.AstaritaG.La RanaG.RussoR.CalignanoA.et al (2005). The Nuclear Receptor Peroxisome Proliferator-Activated Receptor-Alpha Mediates the Anti-inflammatory Actions of Palmitoylethanolamide. Mol. Pharmacol.67 (1), 15–19. 10.1124/mol.104.006353
70
MatsudaL. A.LolaitS. J.BrownsteinM. J.YoungA. C.BonnerT. I. (1990). Structure of a Cannabinoid Receptor and Functional Expression of the Cloned cDNA. Nature346 (6284), 561–564. 10.1038/346561a0
71
McHughD.TannerC.MechoulamR.PertweeR. G.RossR. A. (2008). Inhibition of Human Neutrophil Chemotaxis by Endogenous Cannabinoids and Phytocannabinoids: Evidence for a Site Distinct from CB1 and CB2. Mol. Pharmacol.73 (2), 441–450. 10.1124/mol.107.041863
72
MontecuccoF.BurgerF.MachF.SteffensS. (2008). CB2 Cannabinoid Receptor Agonist JWH-015 Modulates Human Monocyte Migration through Defined Intracellular Signaling Pathways. Am. J. Physiol. Heart Circ. Physiol.294 (3), H1145–H1155. 10.1152/ajpheart.01328.2007
73
MontecuccoF.Di MarzoV.da SilvaR. F.VuilleumierN.CapettiniL.LengletS.et al (2012). The Activation of the Cannabinoid Receptor Type 2 Reduces Neutrophilic Protease-Mediated Vulnerability in Atherosclerotic Plaques. Eur. Heart J.33 (7), 846–856. 10.1093/eurheartj/ehr449
74
MullE. S.ErdemG.NicolK.AdlerB.ShellR. (2020). Eosinophilic Pneumonia and Lymphadenopathy Associated with Vaping and Tetrahydrocannabinol Use. Pediatrics145 (4). 10.1542/peds.2019-3007
75
MunroS.ThomasK. L.Abu-ShaarM. (1993). Molecular Characterization of a Peripheral Receptor for Cannabinoids. Nature365 (6441), 61–65. 10.1038/365061a0
76
NatarajanA.ShahP.MirrakhimovA. E.HussainN. (20132013). Eosinophilic Pneumonia Associated with Concomitant Cigarette and Marijuana Smoking. BMJ Case Rep.. 10.1136/bcr-2013-009001
77
NilssonO.FowlerC. J.JacobssonS. O. (2006). The Cannabinoid Agonist WIN 55,212-2 Inhibits TNF-Alpha-Induced Neutrophil Transmigration across ECV304 Cells. Eur. J. Pharmacol.547 (1-3), 165–173. 10.1016/j.ejphar.2006.07.016
78
ÖcalN.DoğanD.ÇiçekA. F.YücelO. E.TozkoparanE. (2016). Acute Eosinophilic Pneumonia with Respiratory Failure Induced by Synthetic Cannabinoid Inhalation. Balkan Med. J.33 (6), 688–690. 10.5152/balkanmedj.2016.151145
79
OkaS.IkedaS.KishimotoS.GokohM.YanagimotoS.WakuK.et al (2004). 2-arachidonoylglycerol, an Endogenous Cannabinoid Receptor Ligand, Induces the Migration of EoL-1 Human Eosinophilic Leukemia Cells and Human Peripheral Blood Eosinophils. J. Leukoc. Biol.76 (5), 1002–1009. 10.1189/jlb.0404252
80
ParlarA.ArslanS. O.DoğanM. F.ÇamS. A.YalçinA.ElibolE.et al (2018). The Exogenous Administration of CB2 Specific Agonist, GW405833, Inhibits Inflammation by Reducing Cytokine Production and Oxidative Stress. Exp. Ther. Med.16 (6), 4900–4908. 10.3892/etm.2018.6753
81
PereiraJ. P.AnJ.XuY.HuangY.CysterJ. G. (2009). Cannabinoid Receptor 2 Mediates the Retention of Immature B Cells in Bone Marrow Sinusoids. Nat. Immunol.10 (4), 403–411. 10.1038/ni.1710
82
RabornE. S.JamersonM.Marciano-CabralF.CabralG. A. (2014). Cannabinoid Inhibits HIV-1 Tat-Stimulated Adhesion of Human Monocyte-like Cells to Extracellular Matrix Proteins. Life Sci.104 (1-2), 15–23. 10.1016/j.lfs.2014.04.008
83
RahamanO.BhattacharyaR.LiuC. S. C.RaychaudhuriD.GhoshA. R.BandopadhyayP.et al (2019). Cutting Edge: Dysregulated Endocannabinoid-Rheostat for Plasmacytoid Dendritic Cell Activation in a Systemic Lupus Endophenotype. J. Immunol.202 (6), 1674–1679. 10.4049/jimmunol.1801521
84
RaviJ.ElbazM.WaniN. A.NasserM. W.GanjuR. K. (2016). Cannabinoid Receptor-2 Agonist Inhibits Macrophage Induced EMT in Non-small Cell Lung Cancer by Downregulation of EGFR Pathway. Mol. Carcinog55 (12), 2063–2076. 10.1002/mc.22451
85
RaymanN.LamK. H.LamanJ. D.SimonsP. J.LöwenbergB.SonneveldP.et al (2004). Distinct Expression Profiles of the Peripheral Cannabinoid Receptor in Lymphoid Tissues Depending on Receptor Activation Status. J. Immunol.172 (4), 2111–2117. 10.4049/jimmunol.172.4.2111
86
RaymanN.LamK. H.Van LeeuwenJ.MulderA. H.BudelL. M.LöwenbergB.et al (2007). The Expression of the Peripheral Cannabinoid Receptor on Cells of the Immune System and Non-Hodgkin's Lymphomas. Leuk. Lymphoma48 (7), 1389–1399. 10.1080/10428190701377030
87
RizzoM. D.CrawfordR. B.BachA.SermetS.AmalfitanoA.KaminskiN. E. (2019). Δ9-Tetrahydrocannabinol Suppresses Monocyte-Mediated Astrocyte Production of Monocyte Chemoattractant Protein 1 and Interleukin-6 in a Toll-Like Receptor 7-Stimulated Human Coculture. J. Pharmacol. Exp. Ther.371 (1), 191–201. 10.1124/jpet.119.260661
88
RobinsonR. H.MeisslerJ. J.Breslow-DeckmanJ. M.GaughanJ.AdlerM. W.EisensteinT. K. (2013). Cannabinoids Inhibit T-Cells via Cannabinoid Receptor 2 in an In Vitro Assay for Graft Rejection, the Mixed Lymphocyte Reaction. J. Neuroimmune Pharmacol.8 (5), 1239–1250. 10.1007/s11481-013-9485-1
89
SánchezC.de CeballosM. L.Gomez del PulgarT.RuedaD.CorbachoC.VelascoG.et al (2001). Inhibition of Glioma Growth In Vivo by Selective Activation of the CB(2) Cannabinoid Receptor. Cancer Res.61 (15), 5784–5789.
90
Sánchez LópezA. J.Román-VegaL.Ramil TojeiroE.GiuffridaA.García-MerinoA. (2015). Regulation of Cannabinoid Receptor Gene Expression and Endocannabinoid Levels in Lymphocyte Subsets by Interferon-β: a Longitudinal Study in Multiple Sclerosis Patients. Clin. Exp. Immunol.179 (1), 119–127. 10.1111/cei.12443
91
SauvagetE.DellamonicaJ.ArlaudK.SanfiorenzoC.BernardinG.PadovaniB.et al (2010). Idiopathic Acute Eosinophilic Pneumonia Requiring ECMO in a Teenager Smoking Tobacco and Cannabis. Pediatr. Pulmonol45 (12), 1246–1249. 10.1002/ppul.21314
92
SoethoudtM.GretherU.FingerleJ.GrimT. W.FezzaF.de PetrocellisL.et al (2017). Cannabinoid CB2 Receptor Ligand Profiling Reveals Biased Signalling and Off-Target Activity. Nat. Commun.8, 13958. 10.1038/ncomms13958
93
StaianoR. I.LoffredoS.BorrielloF.IannottiF. A.PiscitelliF.OrlandoP.et al (2016). Human Lung-Resident Macrophages Express CB1 and CB2 Receptors Whose Activation Inhibits the Release of Angiogenic and Lymphangiogenic Factors. J. Leukoc. Biol.99 (4), 531–540. 10.1189/jlb.3HI1214-584R
94
TanikawaT.KurohaneK.ImaiY. (2007). Induction of Preferential Chemotaxis of Unstimulated B-Lymphocytes by 2-arachidonoylglycerol in Immunized Mice. Microbiol. Immunol.51 (10), 1013–1019. 10.1111/j.1348-0421.2007.tb03985.x
95
TariqueA. A.EvronT.ZhangG.TepperM. A.MorshedM. M.AndersenI. S. G.et al (2020). Anti-inflammatory Effects of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, on Macrophages from Cystic Fibrosis. J. Cyst Fibros19 (5), 823–829. 10.1016/j.jcf.2020.03.015
96
TiberiM.EvronT.SaraciniS.BoffaL.MercuriN. B.ChintalacharuvuS. R.et al (2021). Potent T Cell-Mediated Anti-inflammatory Role of the Selective CB2 Agonist Lenabasum in Multiple Sclerosis. Neuropathol. Appl. Neurobiol..
97
TurcotteC.BlanchetM. R.LavioletteM.FlamandN. (2016). The CB2 Receptor and its Role as a Regulator of Inflammation. Cell Mol Life Sci73 (23), 4449–4470. 10.1007/s00018-016-2300-4
98
TurcotteC.ChouinardF.LefebvreJ. S.FlamandN. (2015). Regulation of Inflammation by Cannabinoids, the Endocannabinoids 2-Arachidonoyl-Glycerol and Arachidonoyl-Ethanolamide, and Their Metabolites. J. Leukoc. Biol.97 (6), 1049–1070. 10.1189/jlb.3RU0115-021R
99
Van SickleM. D.DuncanM.KingsleyP. J.MouihateA.UrbaniP.MackieK.et al (2005). Identification and Functional Characterization of Brainstem Cannabinoid CB2 Receptors. Science310 (5746), 329–332. 10.1126/science.1115740
100
WangL. L.ZhaoR.LiJ. Y.LiS. S.LiuM.WangM.et al (2016). Pharmacological Activation of Cannabinoid 2 Receptor Attenuates Inflammation, Fibrogenesis, and Promotes Re-epithelialization during Skin Wound Healing. Eur. J. Pharmacol.786, 128–136. 10.1016/j.ejphar.2016.06.006
101
WilliamsJ. C.AppelbergS.GoldbergerB. A.KleinT. W.SleasmanJ. W.GoodenowM. M. (2014). Δ(9)-Tetrahydrocannabinol Treatment during Human Monocyte Differentiation Reduces Macrophage Susceptibility to HIV-1 Infection. J. Neuroimmune Pharmacol.9 (3), 369–379. 10.1007/s11481-014-9527-3
102
YuanM.KiertscherS. M.ChengQ.ZoumalanR.TashkinD. P.RothM. D. (2002). Delta 9-Tetrahydrocannabinol Regulates Th1/Th2 Cytokine Balance in Activated Human T Cells. J. Neuroimmunol133 (1-2), 124–131. 10.1016/s0165-5728(02)00370-3
103
ZhaoY.YuanZ.LiuY.XueJ.TianY.LiuW.et al (2010). Activation of Cannabinoid CB2 Receptor Ameliorates Atherosclerosis Associated with Suppression of Adhesion Molecules. J. Cardiovasc. Pharmacol.55 (3), 292–298. 10.1097/FJC.0b013e3181d2644d
104
ZhouL.ZhouS.YangP.TianY.FengZ.XieX. Q.et al (2018). Targeted Inhibition of the Type 2 Cannabinoid Receptor Is a Novel Approach to Reduce Renal Fibrosis. Kidney Int.94 (4), 756–772. 10.1016/j.kint.2018.05.023
105
ZhouX.YangL.FanX.ZhaoX.ChangN.YangL.et al (2020). Neutrophil Chemotaxis and NETosis in Murine Chronic Liver Injury via Cannabinoid Receptor 1/Gαi/o/ROS/P38 MAPK Signaling Pathway. Cells9 (2). 10.3390/cells9020373
Summary
Keywords
CB2 receptor, eosinophil, neutrophil, monocyte, lymphocyte, inflammation, asthma, allergy
Citation
Simard M, Rakotoarivelo V, Di Marzo V and Flamand N (2022) Expression and Functions of the CB2 Receptor in Human Leukocytes. Front. Pharmacol. 13:826400. doi: 10.3389/fphar.2022.826400
Received
30 November 2021
Accepted
14 January 2022
Published
22 February 2022
Volume
13 - 2022
Edited by
Pal Pacher, National Institute on Alcohol Abuse and Alcoholism (NIAAA), United States
Reviewed by
Valeria Gasperi, University of Rome Tor Vergata, Italy
Updates
Copyright
© 2022 Simard, Rakotoarivelo, Di Marzo and Flamand.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Nicolas Flamand, Nicolas.Flamand@criucpq.ulaval.ca
This article was submitted to Experimental Pharmacology and Drug Discovery, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.